High Purity 99% Raw Material Low MOQ Without Middleman Competitive Price
TDS 5 Inquiries
446036-97-1
Reagent Grade
99.9%
深圳
yixin
10vials/box 40mg*10vials
2026-08-31
polypeptide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificatesBasic Info
-
Product Name:
CJC -1295 whitout DAC
Other Name:L-Argininamide, L-tyrosyl-D-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-glutaminyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-leucyl-L-seryl-;L-tyrosyl-D-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-glutaminyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-leucyl-L-seryl-L-argininamide;CJC -1295 whitout DAC;CIC-1295 With DAC
CAS No.:446036-97-1
Molecular Formula:C152H252N44O42
Molecular Weight:3367.9
Categories:
Characteristics-
Density:
1.43±0.1 g/cm3(Predicted)
Critical Temperature & Pressure:Store at -20°C
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
polypeptide
-
Location:
No. 4, 4th Floor, Building D1, Bili La Park, Lu Shang Road, Dongcheng Street, Economic and Technological Development Zone, Liaocheng City, Shandong Province
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
101-200
-
Year of Establishment:
2025
-
Certifications:
Tirzepatide,Tirzepatide
-
-
Inquiry History5 Inquiries
Country Product Purchase Quantity Date Posted 
Croatia
CJC 1295 DAC
100 MG Jul 6, 2024 
South Korea
steroid oil
10 L Nov 30, 2023 
Germany
CJ-C-1295 Whitout DAC
10 Mar 2, 2026 
United States
CJC 1295 DAC
100 MG Jul 25, 2025 
United Kingdom
Roids sarm
1 MT Mar 7, 2024 Post an enquiry for this product
Tirzepatide (LY3298176) is a dual glucose-dependent polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide. Tirzepatide, also known as LY 3298176, is a dual glucose-dependent polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. Tirzepatide was approved for improving blood sugar control in adults with type 2 diabetes, as an additio 
